aibioRocket Pharmaceuticals secures credit facility of up to $150 million from Hercules
Rocket Pharmaceuticals received $35 million at closing under a credit facility of up to $150 million with Hercules Capital. The company expects its cash, with that first draw, to fund operations into the third quarter of 2028, and it says more borrowing could extend that into 2029.
Key facts
- Companies
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), Hercules Capital, Inc. (NYSE: HTGC)
- News type
- Debt Financing
- Primary source
- Rocket Pharmaceuticals, Inc. 8-K (2026-10-06)
The facility
Rocket Pharmaceuticals, Inc. announced on October 6, 2026 that it had entered into a credit facility agreement with Hercules Capital, Inc. for up to $150 million. Hercules trades on the New York Stock Exchange under HTGC. The company received $35 million at closing and may draw another $35 million at its option during specified periods, subject to the terms of the agreement.
A further $30 million may become available on the achievement of a specified Danon disease clinical milestone. The remaining $50 million is subject to approval by Hercules' investment committee. The facility has an initial 30-month interest-only period and a 48-month maturity, with extensions available on the achievement of specified milestones. The financing also includes warrants to buy Rocket common stock. The release does not give the number of warrant shares or their exercise price.
Hercules' life sciences group head, R. Bryan Jadot, described the deal as a flexible financing solution that supports the company's development priorities. Rocket's chief executive, Gaurav Shah, M.D., said the staged structure lets the company tie additional funding to progress across its programs. The company says the deal builds on the sale of a priority review voucher, and that it diversifies Rocket's sources of capital.
The cash runway
As of June 30, 2026, Rocket had cash, cash equivalents and investments of $283.7 million. That balance is made up of $224.5 million in cash and cash equivalents and $59.2 million in short-term investments. The company expects those resources, together with the first $35 million drawn under the facility, to fund planned operations into the third quarter of 2028.
Additional borrowings could extend the runway into 2029. The company makes that extension subject to the satisfaction of borrowing conditions and depends on the timing and size of future draws and on its operating spending. The $50 million tranche needs committee approval, and the $30 million tranche needs a clinical milestone. Neither is within the company's sole control.
Covenants and the risks Rocket lists
The company's cautionary statement lists the terms it must meet. It names the ability to satisfy the conditions for additional borrowings or extensions, and the availability and timing of future advances, including Hercules' approval of the final tranche. It also names the ability to comply with the facility's covenants, including applicable minimum-cash requirements, and to meet its debt service and repayment obligations. Other restrictions and obligations under the credit facility are listed as risks. The release does not give the level of that covenant.
The losses behind the loan
Rocket's annual report for 2025, filed on February 26, 2026, shows no revenue in either 2025 or 2024. Research and development expense fell to $142.0 million in 2025 from $171.2 million in 2024. The net loss was $223.1 million in 2025, against $258.7 million a year earlier. Cash used in operations was $190.0 million in 2025, down from $209.7 million in 2024.
At the end of 2025 the company held $77.6 million in cash and cash equivalents and $111.4 million in short-term investments, down from $163.6 million and $208.7 million a year earlier. The $283.7 million reported for June 30, 2026 is well above that year-end total; the release does not say what raised it beyond the voucher sale it mentions.
The pipeline the loan supports
The release says the facility supports the pivotal Phase 2 study of RP-A501 for Danon disease and the company's wider cardiovascular pipeline. Rocket describes that pipeline as three clinical-stage gene therapy programs aimed at hypertrophic, arrhythmogenic and dilated cardiomyopathies. The company also describes additional programs in hematology and immunology.
The release gives no enrollment figure, no data timing and no cost for the Danon study. The filing's cautionary statement lists unexpected safety events, the results, timing and costs of trials, and the timing and outcome of regulatory interactions among the factors that could change its plans.
Advisers and the timing
LifeSci Capital served as financial advisor to Rocket on the term loan financing. PJT served as capital markets advisor. The release names no legal counsel for either side and no interest rate, fees or warrant coverage.
What comes next
The $35 million option depends on the company's own decision to draw. The $30 million depends on the Danon milestone, and the $50 million on Hercules' committee. Until those come through, the stated runway reaches only the third quarter of 2028.